BIOFORCE NANOSCIENCES HOLDINGS, INC.

BioForce Nanosciences Holdings, Inc. announced a significant strategic pivot, changing its business operations from vitamin supplements to the oil and gas industry in June 2026. This change followed Nexus Capital Investments, Inc. becoming the majority shareholder in April 2026. For the second quarter ended June 30, 2026, the company reported a net income of $238,682, a substantial improvement from a net loss of $122,781 in the prior year, largely due to debt forgiveness and a legal settlement. The company also appointed new management and established an advisory board.

Bioforce Nanosciences Holdings, Inc. announced that the US Bureau of Land Management (BLM) has approved the transfer of 11 federal oil and gas leases, granting the company exploration rights to approximately 19,957 acres in Nye County, Nevada. While the company plans to commence exploration and development activities, including drilling and seismic surveys, it noted that no proven reserves have been established and there is no assurance of productive operations. The leases have 10-year primary terms and require a 12.5% royalty on production revenues.

Bioforce Nanosciences Holdings, Inc. received an assignment of federal oil and gas leases covering approximately 19,957 acres in Nye County, Nevada, from Natural Minerals Trust, LLC, an entity controlled by its majority shareholder. This move is a key step in the company's strategic pivot from vitamin supplement operations to oil and gas exploration and production. The assignment is pending approval from the United States Bureau of Land Management, and there is no assurance of approval or successful development. Bioforce has engaged Ryder Scott to advise on potential development and reserve evaluations.

BIOFORCE NANOSCIENCES HOLDINGS, INC. announced a change in control as Merle Ferguson sold his 79.65% controlling stake, comprising 26,700,000 shares, to Nexus Capital Investments, Inc. for $400,000. This transaction was followed by significant management changes, including the resignations of Co-CEOs Steven Gagnon and John LaViolette, and Vice-President Sasha Shapiro. The Board appointed Scott Mager as a new Director and named Richard Kaiser as interim CEO, who also continues as CFO and Secretary. Additionally, the company is undergoing a major strategic pivot, shifting its business focus from the vitamin supplement industry to the oil and gas industry.

BIOFORCE NANOSCIENCES HOLDINGS, INC. reported a net loss of $(102,411) for the three months ended March 31, 2026, a substantial improvement from a net loss of $(935,457) in the prior year period, partly due to a $15,322 legal settlement. Despite the improved financial performance, the company continues to face recurring losses and has a going concern issue with zero sales. In a significant corporate action, director Merle Ferguson sold his controlling 80% stock interest to Nexus Capital Investments, Inc. and forgave all his accrued compensation and other amounts due.

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company confirmed its status as a non-accelerated filer and a smaller reporting company, having met all SEC filing requirements over the past year. The aggregate market value of common equity held by non-affiliates was approximately $2,629,690 as of June 30, 2025.